March 2026 Research Update

This month added more detail on how vutrisiran may affect day-to-day symptoms and quality of life for people with ATTR cardiomyopathy over time. Instead of only reporting an overall score, the analysis found small, consistent advantages across several specific areas of how people feel and function compared with placebo. The clearest differences were in physical activities and in feeling discouraged by heart failure, which helps make the trial result easier to picture in real life. [1]

In this post hoc analysis of the HELIOS-B trial, people taking vutrisiran generally had modest improvements across many parts of the Kansas City Cardiomyopathy Questionnaire, a patient survey about symptoms, physical limits, and quality of life. Some of the largest differences favored tasks like hurrying or jogging and walking on level ground, and there was also improvement in the item related to feeling discouraged. The report also noted that the usual drop in these scores with older age appeared less steep with vutrisiran than with placebo, though this was still within the trial context and does not describe what will happen for any one person. [1]

For patients and caregivers, this adds a clearer picture of what the trial-measured benefit looked like: not a dramatic change, but small differences across several everyday experiences such as walking and emotional burden. This is evidence from a randomized trial, so it is stronger than anecdotal reports, but it still reflects averages and a specific study population. What remains uncertain from this analysis is how these questionnaire changes line up with other outcomes a person may care about, and how well these detailed patterns apply across the full range of wild-type ATTR cardiomyopathy in routine care. [1]

Across large real-world cohorts, this month reinforced that ATTR heart disease is not one uniform condition, and that people can have meaningfully different outlooks depending on heart function patterns and accompanying features. Measures from heart imaging helped sort people into higher- and lower-risk groups, and common earlier problems like carpal tunnel syndrome or spinal stenosis identified a group that, on average, had lower death rates and started tafamidis sooner. These studies do not prove cause and effect, but they sharpen the picture of which clinical patterns tend to travel together. [2] [3]

In a cohort of 2,244 people with cardiac amyloidosis (including 1,137 with wild-type ATTR), survival differed across left ventricular ejection fraction patterns: HFpEF was most common, but 39% had mid-range or reduced ejection fraction. A model that combined ejection fraction with two additional imaging measures (a measure of heart muscle squeeze and a measure related to forward blood flow) separated patients into four prognostic groups, and the pattern held up in a separate validation cohort. In plain language, adding more than one heart function measure gave a clearer separation between people who tended to do better or worse over time. [2]

In 1,449 people with wild-type ATTR cardiomyopathy, bilateral carpal tunnel syndrome and lumbar spinal stenosis were often present before the heart diagnosis (29% and 22%). People with either of these history features had lower mortality in the study, and they also started tafamidis more often and earlier than those without these features. One way to interpret this pattern is that these earlier problems may help ATTRwt-CM get recognized sooner in some people, although the study design cannot confirm that earlier recognition is the reason outcomes differed. [3]

A separate multicenter analysis compared a common blood marker of heart strain (NT-proBNP) between Black and White patients with wild-type ATTR cardiomyopathy. NT-proBNP was higher in Black patients before adjustment, but the difference became smaller after accounting for other clinical signs linked to disease severity. This helps clarify that group-level differences in a single lab value may reflect differences in disease presentation and related health factors, not only biology. [4]

For patients, these studies add context for why two people with the same diagnosis may have different paths: the pattern of heart pumping function and other heart measurements can matter, and certain earlier problems like carpal tunnel syndrome may mark a subgroup that is recognized and treated sooner in practice. The evidence here comes from observational cohorts, so it is best viewed as improving understanding and forecasting at the group level rather than predicting an individual person. What remains uncertain is how to use these patterns to make specific individual predictions, and how much the lower mortality seen with carpal tunnel syndrome or spinal stenosis reflects earlier diagnosis versus other differences between patient groups. [2] [3] [4]

This month brought several practical clues that ATTR heart involvement may be missed if people rely on a single classic sign, and that a combination of findings can reduce uncertainty. Studies looking at ECG and ultrasound reported that electrical changes in the heart can show up years before diagnosis, while low ECG voltage was often absent. Another imaging approach, adding a left atrial strain measure, improved detection of high filling pressures and reduced unclear results. Together, these findings point to earlier and more reliable recognition using patterns rather than one test feature. [5] [6] [7]

In a Swedish center study following 63 people with ATTR cardiomyopathy backward in time, ECG abnormalities were common 3 to 5 years before diagnosis and tended to progress, including longer PR, QRS, and QTc intervals and a leftward shift of the electrical axis. Low ECG voltages stayed uncommon both before and at diagnosis. Heart structure changes on ultrasound were present but appeared to lag behind the electrical changes, supporting the idea that conduction changes can be an early signal in some patients. [5]

In a separate cohort describing how 63 people with ATTR were diagnosed in routine practice, many diagnoses occurred in neurology clinics and peripheral neuropathy was a frequent red flag symptom. The report also emphasized that the absence of low ECG voltage did not rule out ATTR, and that other ECG patterns can still be compatible with the disease. This adds a reminder that ATTR can present through nerve symptoms and that ECG patterns are varied, especially outside of specialized centers. [6]

In 100 people with transthyretin amyloid cardiomyopathy (including 24 with wild-type ATTR), severe restrictive filling on ultrasound was not common overall but was more frequent in the wild-type group than the hereditary group. When the researchers added a measure of how the left atrium stretches during filling (left atrial reservoir strain), they detected elevated filling pressures more often and reduced the number of indeterminate cases. In simple terms, this extra measurement may help clarify whether the heart is under high filling pressure when standard ultrasound measures leave uncertainty. [7]

For patients and caregivers, these studies mainly add understanding about recognition and testing rather than describing new treatments. They help clarify that low ECG voltage is not required for ATTR, and that certain ECG changes and added ultrasound measures may provide earlier or clearer signals in some people. The uncertainty is that these are center-based observational studies, and they do not prove that using these signals will always lead to earlier diagnosis or better outcomes for every patient. Even so, they give a more realistic picture of how ATTR can appear in real life and why diagnosis may take time. [5] [6] [7]